{"entity":{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","aka":["Dizal Pharmaceuticals","Dizal (Jiangsu) Pharmaceutical Co., Ltd.","迪哲医药"],"tldr":"Dizal is a Shanghai biotechnology company built on small-molecule kinase inhibitors: sunvozertinib for EGFR exon 20 insertion lung cancer and DZD8586, a dual LYN and BTK inhibitor in the phase 3 TAI-SHAN6 trial for relapsed chronic lymphocytic leukaemia.","summary":"Dizal Pharmaceutical, based in Shanghai and listed in Shanghai, designs small-molecule drugs for cancer and immune disease. Its oncology pipeline centres on sunvozertinib, an EGFR inhibitor designed for exon 20 insertion mutations in non-small-cell lung cancer, and DZD8586, an oral inhibitor of LYN and BTK that crosses the blood-brain barrier and is being compared with investigator's choice therapy in relapsed or refractory chronic lymphocytic leukaemia. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.dizalpharma.com/"},{"label":"ClinicalTrials.gov: trials led by Dizal","url":"https://clinicaltrials.gov/search?lead=Dizal"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","cll"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["sunvozertinib","dzd8586","golidocitinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["tai-shan6","nct05668988","nct05712902","nct03974022","nct07079475","nct07059650","nct07070440","nct06295432","nct07328217","nct07496229","nct06276283","nct07154264","nct06539182"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.dizalpharma.com/","stage":"public","investors":[],"funding":[]},"route":"/companies/dizal/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"dzd8586","kind":"drug","name":"DZD8586","route":"/drugs/dzd8586/"},{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/"},{"id":"sunvozertinib","kind":"drug","name":"Sunvozertinib","route":"/drugs/sunvozertinib/"}],"trial":[{"id":"nct07328217","kind":"trial","name":"A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors","route":"/trials/nct07328217/"},{"id":"nct07234162","kind":"trial","name":"A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)","route":"/trials/nct07234162/"},{"id":"nct07182682","kind":"trial","name":"A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins","route":"/trials/nct07182682/"},{"id":"nct06295432","kind":"trial","name":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","route":"/trials/nct06295432/"},{"id":"nct07154264","kind":"trial","name":"A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)","route":"/trials/nct07154264/"},{"id":"tai-shan6","kind":"trial","name":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","route":"/trials/tai-shan6/"},{"id":"nct05668988","kind":"trial","name":"A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)","route":"/trials/nct05668988/"},{"id":"nct03974022","kind":"trial","name":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","route":"/trials/nct03974022/"},{"id":"nct07496229","kind":"trial","name":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","route":"/trials/nct07496229/"},{"id":"nct07070440","kind":"trial","name":"DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)","route":"/trials/nct07070440/"},{"id":"nct07059650","kind":"trial","name":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","route":"/trials/nct07059650/"},{"id":"nct06539182","kind":"trial","name":"DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)","route":"/trials/nct06539182/"},{"id":"nct06276283","kind":"trial","name":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","route":"/trials/nct06276283/"},{"id":"nct06198907","kind":"trial","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","route":"/trials/nct06198907/"},{"id":"nct07110103","kind":"trial","name":"Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC","route":"/trials/nct07110103/"},{"id":"nct06864624","kind":"trial","name":"Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC","route":"/trials/nct06864624/"},{"id":"nct07079475","kind":"trial","name":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","route":"/trials/nct07079475/"},{"id":"nct05712902","kind":"trial","name":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","route":"/trials/nct05712902/"}]}}